Oragenics (OGEN) 10-Q 13 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 08, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	OGEN
Entity Registrant Name	ORAGENICS INC
Entity Central Index Key	1,174,940
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		11,837,635

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,940,530	$ 6,166,143
Prepaid expenses and other current assets	1,257,440	1,027,029
Total current assets	5,197,970	7,193,172
Property and equipment, net	10,643	21,659
Total assets	5,208,613	7,214,831
Current liabilities:
Accounts payable and accrued expenses	1,537,121	818,044
Short-term notes payable	20,912	80,478
Total current liabilities	1,558,033	898,522
Shareholders' equity:
Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 and 12,000,000 Series A shares, 6,600,000 and 6,600,000 Series B shares, 101.733 and 100 Series C shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	6,100,182	6,309,608
Common stock, $0.001 par value; 200,000,000 shares authorized 6,102,635 and 4,928,335 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	6,103	4,928
Additional paid-in capital	103,404,448	101,402,570
Accumulated deficit	(105,860,153)	(101,400,797)
Total shareholders' equity	3,650,580	6,316,309
Total liabilities and shareholders' equity	$ 5,208,613	$ 7,214,831

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, par value
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	6,102,635	4,928,335
Common stock, shares outstanding	6,102,635	4,928,335
Series A Preferred Stock [Member]
Preferred stock, shares issued	9,417,000	12,000,000
Preferred stock, shares outstanding	9,417,000	12,000,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	6,600,000	6,600,000
Preferred stock, shares outstanding	6,600,000	6,600,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	101.733	100
Preferred stock, shares outstanding	101.733	100

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
Research and development	$ 1,271,542	$ 605,411	$ 2,597,783	$ 1,727,872
General and administrative	1,012,007	791,348	1,807,470	1,656,543
Total operating expenses	2,283,549	1,396,759	4,405,253	3,384,415
Loss from continuing operations	(2,283,549)	(1,396,759)	(4,405,253)	(3,384,415)
Other income (expense):
Interest income	3,254	1,832	6,728	3,767
Interest expense	(664)	(57,865)	(1,501)	(58,666)
Change in value of derivative liability		231,644		231,644
Local business tax	(330)	(1,200)	(660)	(2,400)
Other income		1,361		6,508
Total other income, net	2,260	175,772	4,567	180,853
Loss from continuing operations before income taxes	(2,281,289)	(1,220,987)	(4,400,686)	(3,203,562)
Income tax benefit	0	0	0	0
Net loss from continuing operations	$ (2,281,289)	$ (1,220,987)	$ (4,400,686)	$ (3,203,562)
Basic and diluted net loss per share from continuing operations	$ (0.38)	$ (0.25)	$ (0.80)	$ (0.65)
Shares used to compute basic and diluted net loss per share from continuing operations	6,028,701	4,928,335	5,509,741	4,924,115
Discontinued operations
Profit from operations of discontinued component		$ 121
Profit from discontinued operations		$ 121
Basic and diluted net profit per share from discontinued operations	$ 0	$ 0	$ 0	$ 0
Shares used to compute basic and diluted net profit per share from discontinued operations	6,028,701	4,928,335	5,509,741	4,924,115
Net loss	$ (2,281,289)	$ (1,220,866)	$ (4,400,686)	$ (3,203,562)
Basic and diluted net loss per share	$ (0.38)	$ (0.25)	$ (0.80)	$ (0.65)
Shares used to compute basic and diluted net loss per share	6,028,701	4,928,335	5,509,741	4,924,115

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (4,400,686)	$ (3,203,562)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,016	35,707
Stock issued as compensation to non-employee directors	24,320	93,828
Stock-based compensation expense	200,310	200,938
Decrease in fair value of derivative liability		(231,644)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(201,496)	(344,656)
Accounts payable and accrued expenses	719,077	(216,119)
Net cash used in operating activities	(3,647,459)	(3,665,508)
Cash flows from financing activities:
Payments on short-term notes payable	(88,481)	(75,801)
Net proceeds from issuance of common stock and warrants	1,510,327
Net proceeds from issuance of convertible preferred stock and warrants		1,238,084
Proceeds from issuance of note payable to shareholder		2,400,000
Proceeds from payment of stock subscription receivable		30,563
Restricted cash (receipts) released, net		(1,919,030)
Net cash provided by financing activities	1,421,846	1,673,816
Net decrease in cash and cash equivalents	(2,225,613)	(1,991,692)
Cash and cash equivalents at beginning of period	6,166,143	4,080,618
Cash and cash equivalents at end of period	3,940,530	2,088,926
Supplemental disclosure of cash flow information:
Interest paid	1,501	1,605
Non-cash investing and financing activities:
Borrowings under short term notes payable for prepaid expense	28,915	31,985
Par value of restricted stock issued	16	$ 160
Stock dividend on Series C preferred stock	58,670
Par value of common stock issued in connection with Series A Preferred Stock Conversion	259
Value of Series A preferred stock converted into common stock	$ 268,096

Organization

Organization	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Oragenics, Inc. (formerly known as Oragen, Inc.) (the “Company” or “we”) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation The accompanying unaudited interim financial statements as of June 30, 2018 and December 31, 2017 (audited) and for the three and six months ended June 30, 2018 and 2017 have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q S-X. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2017, which are included in our Annual Report on Form 10-K $-0- The Company expects to incur substantial expenditures to further develop each of its technologies. The Company believes the working capital at June 30, 2018, together with its recently completed underwritten public offering (See Note 10) of its equity securities, will be sufficient to meet the business objectives as presently structured through June of 2019. As such, there is substantial doubt that we can continue as a going concern beyond that date. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current shareholders may experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company may be required to curtail its current development programs, cut operating costs and forego future development and other opportunities.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Recently Issued Accounting Pronouncements In June 2018, the Financial Accounting Standards Board issued Accounting Standards Update 2018-07 Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this Update expand the scope of Topic 718 to include sharebased payment transactions for acquiring goods and services from nonemployees. The requirements of Topic 718 should be applied to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The adoption of this guidance is not expected to have a material impact on the Company’s results of operation, financial position or disclosures. In February 2016, the FASB issued guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Previous lease accounting was criticized for failing to meet the needs of users of financial statements because it did not always provide a faithful representation of leasing transactions. In particular, it did not require lessees to recognize assets and liabilities arising from operating leases on the balance sheet. The guidance is effective for annual and interim periods beginning after December 15, 2018. The adoption of this guidance is not expected to have a material impact on the Company’s results of operation, financial position or disclosures. There are no additional accounting pronouncements issued or effective during the three or six months ended June 30, 2018 that have had, or are expected to have, an impact on our financial statements. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, and income tax valuation allowance. Inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts were the principal areas of estimation that had been reflected in the financial statements related to discontinued operations. Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, warrants, and restricted stock grants are measured at their fair value on the awards’ grant date typically using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued. Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding. Revenue Recognition During the quarter ended June 30, 2016, the Company sold its consumer probiotic business, from which it had historically generated revenues. As a result of this sale, the Company is no longer generating revenues. Concentrations In June of 2016, the Company sold its consumer probiotics business, as such the Company is no longer dependent on key suppliers to continue to operate the consumer probiotics business. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2018, the uninsured portion of this balance was $3,690,530. As of December 31, 2017, the uninsured portion of this balance was $5,916,143.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	4. Stock-based Compensation The Company recognized stock-based compensation on all employee and non-employee For the For the For the Six For the Six Research and development $ 9,192 $ 5,643 $ 18,048 $ 12,257 General and administrative 97,114 117,105 206,582 282,509 Total Stock based compensation $ 106,306 $ 122,748 $ 224,630 $ 294,766 At our Annual Meeting of Shareholders held on June 22, 2018, our shareholders approved an amendment to our 2012 Equity Incentive Plan to increase the shares available for awards thereunder by 1,500,000 shares. The Company granted 128,000 and 128,000 stock options, with a weighted-average grant date fair value of $1.52 and $1.52 per share, during three and six months ended June 30, 2018, respectively. The Company granted 105,600 and 105,600 stock options, with a weighted-average grant date fair value of $3.60 and $3.60 per share, during the three and six months ended June 30, 2017, respectively. During the six months ended June 30, 2018, 116,199 stock options previously granted have vested and no stock options were forfeited and no stock options were exercised. On June 22, 2018, in connection with, and in furtherance of, the non-employee non-employee Also, on June 22, 2018, and in connection with, and in furtherance of, the non-employee non-employee In addition, on June 22, 2018, in connection with, and in furtherance of, the equity based award program, the Board approved stock option awards in the amount of 62,000 to management and 10,000 to staff under the Company’s 2012 Equity Incentive Plan at an exercise price of $1.52 per share, the closing price on June 22, 2018, the date of the grant. On June 22, 2017, in connection with, and in furtherance of, the non-employee non-employee In addition, on June 22, 2017, in connection with, and in furtherance of, the new equity based award program, the Board approved stock option awards in the amount of 45,500 to management and 4,100 to staff under the Company’s 2012 Equity Incentive Plan at an exercise price of $3.70 per share, the closing price on June 22, 2017, the date of the grant. On February 9, 2017, in connection with, and in furtherance of, the non-employee non-employee Each executive officer and non-employee non-employee

Warrants

Warrants	6 Months Ended
	Jun. 30, 2018
Text Block [Abstract]
Warrants	5. Warrants On April 6, 2018 (the “Closing Date”), the Company entered into a securities purchase agreement with certain new institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock in a registered direct offering. The Company also issued unregistered warrants to the investors in a concurrent private placement to purchase up to an equivalent number of shares of the Company’s common stock with an exercise price of $2.00 per share. The warrants are exercisable six months following the Closing Date and will expire five years from the date of issuance. A summary of warrant activity for the year ended December 31, 2017 and the six months ended June 30, 2018 is as follows: Warrants Weighted Average Price Balance - December 31, 2016 17,559 $ 1.50 Granted 2,177,425 3.10 Exercised — — Expired (17,559 ) 1.50 Balance - December 31, 2017 2,177,425 3.10 Granted 900,000 2.00 Exercised — — Expired — — Balance - June 30, 2018 3,077,425 $ 2.78 The warrants outstanding as of June 30, 2018 are as follows: Exercise Price Warrants Outstanding Expiration Date $ 3.10 48,387 9/19/2022 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 2.00 900,000 4/10/2023 3,077,425

Short-Term Notes Payable

Short-Term Notes Payable	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Short-Term Notes Payable	6. Short-Term Notes Payable As of June 30, 2018 and December 31, 2017, the Company had $20,912 and $80,478, respectively, in short-term notes payable for the financing of various insurance policies. Products Liability Insurance On March 1, 2016, the Company entered into a short-term note payable for $49,395 bearing interest at 5.93% per annum to finance the product liability insurance. Principal and interest payments on this note began April 10, 2016 and are made evenly based on a straight line amortization over a 10-month On March 10, 2017, the Company entered into a short-term note payable for $31,985 bearing interest at 6.18% per annum to finance the product liability insurance. Principal and interest payments on this note began April 10, 2017 and are made evenly based on a straight line amortization over a 10-month On March 10, 2018, the Company entered into a short-term note payable for $28,915 bearing interest at 5.09% per annum to finance the product liability insurance. Principal and interest payments on this note began April 10, 2018 and are made evenly based on a straight line amortization over a 11-month Directors’ and Officers’ Insurance On July 24, 2016, the Company entered into a short-term note payable for $111,730 bearing interest at 4.89% to finance a portion of the directors’ and officers’ liability insurance and employment practices liability insurance premiums. Principal and interest payments on this note began August 24, 2016 and are made evenly based on a straight line amortization over an 11-month On July 24, 2017, the Company entered into a short-term note payable for $140,062 bearing interest at 5.09% to finance a portion of the directors’ and officers’ liability insurance and employment practices liability insurance premiums. Principal and interest payments on this note began August 24, 2017 and are made evenly based on a straight line amortization over an 11-month

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies The University of Florida Research Foundation Licenses (“UFRF”) UFRF-MU1140 License. one-time one-time one-time one-time one-time The Company is required to make minimum annual maintenance payments to the UFRF for the term of the amended license agreement in the amount of $10,000 for the license agreement. The aggregate minimum annual payments are required to be paid in advance on a quarterly basis (i.e. $2,500 per quarter) for the license. The Company must also pay all patent costs and expenses incurred by the UFRF for the preparation, filing, prosecution, issuance and maintenance of the patents. The terms of the UFRF amended license agreement expire upon the earlier of (i) the date that no patents covered by the amended license agreement remain enforceable or (ii) the payment of earned royalties under the amended license agreement, once begun, ceases for more than three calendar quarters. The Company may voluntarily terminate the license agreement upon 90 days written notice to UFRF. UFRF may terminate the amended license agreement if the Company breaches its obligations to timely pay any amounts due under the amended license agreement, to submit development reports as required under the amended license agreement or commit any other breach of any other covenants contained in the amended license agreement and the Company fails to remedy such breach within 90 days after written notice of such breach by UFRF. Texas A&M License Agreement Under the terms of the Texas A&M license agreement, the Company made an initial payment of five thousand dollars ($5,000) to Texas A&M. The Company must also pay to Texas A&M a royalty of five percent (5%) of net sales of products that include the licensed technology, subject to royalty stacking provisions with a two percent (2%) minimum royalty. Additionally, in order to maintain the exclusive license, commencing in 2014 and each year thereafter prior to the calendar year of the first sale of products using the licensed technology, the Company was to pay Texas A&M $15,000 as minimum annual consideration for the continuation of the license agreement. In October of 2016 the Texas A&M license agreement was amended to provide for a payment of $25,000 commencing in 2017 and each year thereafter prior to the calendar year of the first sale of products using the licensed technology, as minimum annual consideration for the continuation of the license agreement. Once the Company commences the sale of products that include the technology the Company licenses from Texas A&M the Company must pay a minimum annual amount of $100,000 to Texas A&M and every year thereafter through the expiration of the Agreement. However, once sales begin, any royalty payments the Company makes on net sales will be credited against the $100,000 required maintenance payment. The Company must also pay all patent costs and expenses for the preparation, filing, prosecution, issuance and maintenance of the patent rights. Sales by sublicensees are subject to the royalty rate above, and the Company is responsible for certain payments to Texas A&M for any other consideration received that are not in the form of a royalty. Pursuant to the amended Texas A&M license agreement, the Company is obligated to meet the following milestones and make milestone payments: (i) enrollment of first patient in a Phase 1 clinical trial using the licensed technology, to occur on or before June 1, 2019, with a milestone achievement payment of $50,000, (ii) completion of Phase 2 clinical trial using the licensed technology to occur on or before June 1, 2022, with a milestone achievement payment of $100,000, (iii) completion of Phase 3 clinical trial of the licensed technology to occur on or before June 1, 2025, with a milestone achievement payment of $150,000, and (iv) first sale of the licensed technology to occur on or before June 1, 2026 with a milestone achievement payment of $400,000. If we fail to accomplish the milestones or fail to achieve net sales of products including the licensed technology for two consecutive calendar years Texas A&M at its sole option may waive the requirement, negotiate the missed milestones or terminate the license agreement. None of the Texas A&M milestones had been achieved as of June 30, 2018. The Lantibiotic ECC Under the Lantibiotic ECC, and subject to certain exceptions, the Company is responsible for, among other things, funding the further anticipated development of lantibiotics toward the goal of commercialization, conducting nonclinical and clinical development of candidate lantibiotics, as well as for other aspects of manufacturing and the commercialization of the product(s). Among other things, Intrexon is responsible for technology discovery efforts, cell-engineering development, certain aspects of the manufacturing process, and costs of filing, prosecution and maintenance of Intrexon’s patents. In November of 2017 the Lantibiotic ECC was amended to: (i) consolidate the development milestone payments into one payment of $25,000,000, being due six months after receiving FDA approval of a New Drug Application, (ii) reduce the sublicense revenue percentage we would have had to pay from 50% to 25% of sublicensing revenue, (iii) reduce the royalty rate from 25% of Product Profit to 10% of Net Sales, (iv) revise the form of milestone payments from being share based or cash at the Company’s election to only cash, and (v) commit that Diligent Efforts (as defined in the Lantibiotic ECC) in pursuing the Lantibiotic Program would be deemed satisfied in 2018 provided that at least $1,200,000 was budgeted for the advancement of the Lantibiotic Program. In November of 2017, the Stock Issuance Agreement was also amended. Under the terms of the amendment, the Company has agreed to make certain payments, in cash, to Intrexon upon our achievement of designated milestones. The milestone events and amounts payable are as follows: (i) a one-time (ii) a one-time (iii) a one-time Pursuant to the terms of the amendment, we will also pay Intrexon on a quarterly basis 10% of Net Sales derived in that quarter from the sale of products developed from the Lantibiotic ECC, calculated on an Oragenics Product-by-Oragenics On July 21, 2016, the Lantibiotics ECC was amended to revise the definition of Field in view of a provisional patent application filing between Intrexon and Oragenics and to further clarify Oragenics’ rights under the Lantibiotic ECC to genetically modified Streptococcus mutans None of the Lantibiotic ECC milestones had been achieved as of June 30, 2018. The Oral Mucositis ECC Under the Oral Mucositis ECC, and subject to certain exceptions, the Company is responsible for, among other things, funding the further anticipated development of products toward the goal of commercialization, conducting preclinical and clinical development of candidate products, as well as for other aspects of manufacturing and the commercialization of the product(s). Among other things, Intrexon is responsible for technology discovery efforts, cell-engineering development, and certain aspects of the manufacturing process. In November of 2017 the Company amended the Oral Mucositis ECC to: (i) consolidate the development milestone payments into one payment of $27,500,000 being due within six months after receiving FDA approval of a New Product Application; (ii) reduce the sublicense revenue percentage from 50% to 25% of sublicensing revenue; and (iii) revise the field in which the Company has exclusive rights to its Oral Mucositis product candidate for the treatment of Oral Mucositis to clarify that the Company has an exclusive for the treatment of Oral Mucositis in humans regardless of etiology. Pursuant to the terms of the Oral Mucositis ECC, as amended, we are obligated to pay Intrexon on a quarterly basis 12% of the net sales derived from the sale of products developed from the exclusive channel collaboration. We are also obligated to pay Intrexon on a quarterly basis, 25% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. In November of 2017, the Stock Issuance Agreement and Oral Mucositis ECC were amended. Under the terms of the amendment, the Company has agreed to make certain payments to Intrexon upon our achievement of designated milestones in the form of shares of our Common Stock (based upon the fair market value of the shares otherwise required to be issued) unless the issuance of such shares would reasonably likely cause Intrexon to consolidate our financial statements with Intrexon’s financial statements, or at our option make a cash payment to Intrexon. The milestone events and amounts payable are as follows: (i) a one-time payment of twenty seven million five hundred thousand United States dollars ($27,500,000) within six (6) months of the achievement of the Regulatory Approval Milestone Event meaning receiving approval from the FDA of a New Product Application for an Oragenics Product (or equivalent regulatory action in a foreign jurisdiction); (ii) a one-time (iii) a one-time None of the Oral Mucositis ECC milestones had been achieved as of June 30, 2018. The Oral Mucositis ECC provides that in the event (i) Oragenics is required to make a milestone payment in cash as an issuance of shares would cause Intrexon to consolidate the Company’s financial statements with Intrexon’s financial statements, and (ii) Oragenics reasonably concludes that a cash milestone payment would have an adverse effect on its working capital needs over the next twelve (12) months, then such cash payment shall be in the form of an interest bearing promissory note with a maturity date of less than twelve (12) months and include other conventional market terms that would not be expected to unreasonably have an adverse effect on Oragenics working capital needs over such twelve (12) month period.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions During the three and six months ended June 30, 2018, we paid $89,216 and $159,233; and during the three and six months ended June 30, 2017 we paid $-0- On June 27, 2016, the Company completed the sale of its consumer probiotics business to ProBiora Health, LLC (“ProBiora Health”), an entity owned by Ms. Christine L. Koski, a director at the time of the transaction. The purchase price was $1,700,000 in cash of which $1,250,000 was paid at closing and $450,000 was payable on or before July 31, 2016. The note accrued interest at the rate of 1% per annum and was paid in full on July 29, 2016. In connection with the sale, ProBiora Health assumed certain liabilities. ProBiora Health is obligated to pay the Company contingent consideration annually over a 10 year period based on a percentage of sales of products using the Purchased Assets, with a maximum obligation to the Company of $2,000,000. No such payment of contingent consideration was due to the Company from ProBiora Health for the years ending December 31, 2017 and December 31, 2016. The activities related to the consumer probiotic business are reflected as part of “Discontinued Operations” for the applicable period presented.

Shareholders Equity

Shareholders Equity	6 Months Ended
	Jun. 30, 2018
Federal Home Loan Banks [Abstract]
Shareholders Equity	9. Shareholders Equity Common Stock Increase in the Number of Authorized Shares and Completion of Reverse Stock Split In January of 2017, we filed an amendment to our Amended and Restated Articles of Incorporation which increased the number of authorized shares of all classes of our capital stock from 120,000,000 shares to 270,000,000 shares by increasing the number of authorized shares of common stock from 100,000,000 shares of common stock to 250,000,000 shares of common stock. The amendment to our Amended and Restated Articles of Incorporation was previously approved by a majority of our shareholders. In addition, a majority of shareholders approved an amendment to our Amended and Restated Articles of Incorporation to effect a reverse stock split of our common stock by a ratio of not less than one-for-five one-for-ten, In December of 2017, we filed another amendment to our Amended and Restated Articles of Incorporation which increased the number of authorized shares of our common stock from 250,000,000 shares to 450,000,000. The amendment to our Amended and Restated Articles of Incorporation was previously approved by a majority of our shareholders. In addition, a majority of shareholders approved an amendment to our Amended and Restated Articles of Incorporation to effect a reverse stock split of our common stock by a ratio of not less than one-for-five one-for-ten, On January 8, 2018, the Company announced a reverse split of its common stock, $0.001 par value, at a ratio of one-for-ten, As a result of the reverse split, each 10 pre-split non-assessable. No fractional shares were issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the one-for-ten On March 9, 2018, a holder of 2,583,000 shares of the Company’s Series A Convertible Preferred Stock, converted the Series A Convertible Preferred Stock into 258,300 shares of the Company’s common stock. On April 6, 2018, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company agreed to issue and sell, in a registered offering by the Company directly to the investors, an aggregate of 900,000 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $2.00 per share. In a concurrent private placement, the Company agreed to issue to the investors who participated in the registered offering, warrants exercisable for one share of common stock for each share purchased in the registered offering for an aggregate of warrants to purchase 900,000 shares of common stock at an exercise price of $2.00 per share. Each warrant is exercisable beginning on the six-month anniversary of the date of its issuance and will expire five years from the date of issuance. At our Annual Meeting of Shareholders held on June 22, 2018, our shareholders approved an amendment to the Company’s Amended and Restated Articles of Incorporation which increased the number of authorized shares of our Common Stock from 45,000,000 shares of Common Stock to 200,000,000 shares of Common Stock. Also, on June 22, 2018, and in connection with, and in furtherance of, the non-employee non-employee On February 9, 2017, in connection with and in furtherance of the new equity based award program (See Note 4), the Board approved the award of 4,000 restricted shares of the Company’s common stock to each of the Company’s non-employee Preferred Stock Series A Non-Voting On May 10, 2017 we entered into a securities purchase agreement with three accredited investors, to purchase up to $3,000,000 of Series A Convertible Preferred Stock (the “Series A Preferred Stock Financing”). The sale of the Preferred Stock took place in two separate closings and at the first closing which occurred on May 10, 2017, we received gross proceeds of approximately $1,302,000. The second closing occurred on July 25, 2017 and we received gross proceeds of approximately $1,698,000, which was the balance of the Preferred Stock Financing. The full $3,000,000 of Preferred Stock, and after giving effect to the reverse stock split, is convertible into 1,200,001 shares of our Common Stock, based on a fixed conversion price of $2.50 per share on an as-converted non-exercisable On July 27, 2017, we entered into an agreement to amend the warrants issued in connection with the Series A Preferred Stock Financing to provide notification and objection requirements with respect to the change of control provisions. The change of control provisions in the warrants had previously caused the warrants to be treated as a derivative liability as opposed to being treated as equity on our balance sheet. The warrants have been replaced by amended and restated warrants containing such notification and objection requirements (the “Amended and Restated Common Stock Purchase Warrants”) so that the Amended and Restated Common Stock Purchase Warrants are now treated as equity on our balance sheet. All other terms of the original warrants remain unchanged by the Amended and Restated Common Stock Purchase Warrants. In connection with the Series A Preferred Financing, we filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Preferred Stock with the Secretary of State of the State of Florida, to be effective May 10, 2017. The number of shares of Preferred Stock designated as Series A Preferred Stock is 12,000,000 and have a par value of $0.001 per share. In connection with the issuance and sale of the Series A Preferred Stock and Series A Warrants, we granted certain demand registration rights and piggyback registration rights with respect to the shares of our Common Stock issuable upon conversion of the Preferred Stock and exercise of the Warrants, pursuant to a Registration Rights Agreement. Except as otherwise required by law, the Series A Preferred Stock shall have no voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, (b) amend its articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (c) increase the number of authorized shares of Series A Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. Upon any liquidation, dissolution or winding-up On March 9, 2018, a holder of 2,583,000 shares of the Company’s Series A Convertible Preferred Stock, converted the Series A Convertible Preferred Stock into 258,300 shares of the Company’s common stock. Series B Non-Voting, On November 8, 2017, we completed a private placement of $3,300,000 of Series B Non-Voting, Convertible The full $3,300,000 of Series B Convertible Preferred Stock is convertible, after giving effect to the reverse stock split, into 1,320,002 shares of our Common Stock, based on a conversion of one share of Series B Preferred Stock into two shares of Common Stock. The purchase price per share of the Series B Preferred Stock is represented by $2.50 per share of the Common Stock on an as converted basis. In addition, and after giving effect to the reverse stock split, we issued to the investors in the private placement accompanying common stock purchase warrants to purchase an aggregate of 1,064,518 shares of Common Stock (the “Series B Warrants”). The Series B Warrants have a term of seven years from the date of issuance and are non-exercisable In connection with the Series B Preferred Financing, we filed a Certificate of Designation and Rights of Series B Convertible Preferred Stock with the Secretary of State of the State of Florida, to be effective November 8, 2017. The number of shares of Preferred Stock designated as Series B Preferred Stock is 6,600,000 and have a par value of $0.001 per share. Except as otherwise required by law, the Series B Preferred Stock shall have no voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend the Certificate of Designation, (b) amend its articles of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (c) increase the number of authorized shares of Series B Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock shall rank (i) on par with the Common Stock and Series A Preferred Stock and junior to Series C Preferred Stock as to dividend rights and (ii) junior to Series C Preferred Stock, on par with Series A Preferred Stock and senior to the Common Stock as to distribution of assets upon liquidation, dissolution or winding-up Upon any liquidation, dissolution or winding-up Series C Non-Voting, Non- Concurrently with the Series B Preferred Stock Financing, we also entered into a Debt Conversion Agreement (the “Intrexon Debt Conversion Agreement”) with Intrexon Corporation (“Intrexon”) pursuant to which Intrexon exchanged the $2,400,000 unsecured non-convertible promissory C, Non-Voting, Non-Convertible Preferred In connection with the Intrexon Debt Conversion Agreement, we filed a Certificate of Designation and Rights of Series C Non-Convertible Each issued and outstanding share of Series C Preferred Stock entitles the holder of record to receive dividends at the annual rate of twelve percent (12%) (the “Initial Rate”) of its Stated Value, payable by issuing additional shares of Series C Preferred Stock within thirty days after the end of each calendar year pro-rata

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	10. Subsequent Event On July 17, 2018, the Company announced the closing of an underwritten public offering (the “Public Offering”) of units for gross proceeds of approximately $13.8 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Public Offering was comprised of Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and a seven-year warrant to purchase one share of common stock with an exercise price of $1.00 per share (each, a “Warrant” and collectively, the “Warrants”), and Class B Units, priced at a public offering price of $1.00 per unit, with each unit comprised of one share of series D preferred stock (the “Series D Preferred Stock”), which is convertible into one share of common stock, and a Warrant. The conversion price of the Series D Preferred Stock issued in the transaction as well as the exercise price of the Warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The Series D Preferred Stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock), liquidation preference or other preferences over common stock, and, with certain exceptions, has no voting rights. The securities comprising the units were immediately separable and have been issued separately. The Conversion Price of the Series D Preferred Stock and exercise price of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, dilutive issuances, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. A total of 4,436,000 shares of common stock, 9,364,000 shares of Series D Preferred Stock convertible into 9,364,000 shares of common stock, and total warrants to purchase 13,800,000 shares of common stock were issued in the Public Offering inclusive of the underwriters exercise of their over-allotment option to purchase 1,800,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock at the Public Offering price per share less the underwriting discounts and commissions. Prior to the closing of the Public Offering, certain purchasers elected to convert shares of Series D Preferred Stock into shares of Common Stock. Following the completion of the Public Offering and the conversion of these shares, the Company had outstanding 8,760,000 shares of Series D Preferred Stock. The net proceeds to the Company from the Public Offering, after deducting Underwriter fees and expenses and the Company’s estimated Public Offering expenses, and excluding the proceeds, if any, from the exercise of the Warrants issued in the Public Offering, was approximately $12.3 million. The Company anticipates using the net proceeds from this Public Offering to continue funding development of AG013, our ongoing Phase II clinical trial for the treatment of Oral Mucositis, our pre-clinical development of our lantibiotics program and for general corporate purposes, including research and development activities, capital expenditures and working capital. The following table sets forth the Company’s Total Shareholders’ Equity position as of June 30, 2018, as adjusted on a pro forma Oragenics, Inc. Pro Forma Shareholder’s Equity (U.S. dollars) Total Shareholders’ Equity as of June 30, 2018 $ 3,650,580 Net Proceeds from July 17, 2018 Public Offering 12,300,000 Pro forma Total Shareholders’ Equity, as of June 30, 2018, as adjusted $ 15,950,580 In connection with the Public Offering, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series D Preferred Stock on July 13, 2018, with the Secretary of State of the State of Florida which became effective upon filing. The Certificate of Designation provides for the issuance of the shares of Series D Preferred Stock. With certain exceptions, the shares of Series D Preferred Stock rank on par with the shares of the Common Stock, in each case, as to dividend rights and distributions of assets upon liquidation, dissolution or winding up of the Company. With certain exceptions, as described in the Certificate of Designation, the shares of Series D Preferred Stock have no voting rights. However, as long as any shares of Series D Preferred Stock remain outstanding, the Certificate of Designation provides that the Company shall not, without the affirmative vote of holders of a majority of the then outstanding shares of Series D Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or alter or amend this Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the Holders, (c) increase the number of authorized shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. Each share of Series D Preferred Stock is convertible at any time at the holder’s option into a number of shares of Common Stock equal to one share divided by the Conversion Price. The “Conversion Price” is initially $1.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions as specified in the Certificate of Designation. Notwithstanding the foregoing, the Certificate of Designation further provides that the Company shall not effect any conversion of the shares of Series D Preferred Stock, with certain exceptions, to the extent that, after giving effect to an attempted conversion, the holder of shares of Series D Preferred (together with such holder’s affiliates and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of Common Stock in excess of 4.99% of the shares of Common Stock then outstanding (or, upon election by a Holder prior to the issuance of and Warrants, 9.99%). At the holder’s option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days’ prior notice to the Company. Additionally, subject to certain exceptions and limitations, at any time prior to the three year anniversary of the issuance of the Series D Preferred Stock, the Company will have the right to cause each holder of the Series D Preferred Stock to convert all or part of such holder’s Series D Preferred Stock in the event that (i) the volume weighted average price of our common stock for each of 30 consecutive trading days exceeds $3.00 (subject to adjustment for stock splits, recapitalizations, stock dividends and similar transactions), (ii) the average daily trading volume for such measurement period exceeds $175,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The description of the Series D Preferred Stock is qualified by reference to the Certificate of Designation filed with our Form 8-K on July 17, 2018.

Significant Accounting Polici16

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2018, the Financial Accounting Standards Board issued Accounting Standards Update 2018-07 Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this Update expand the scope of Topic 718 to include sharebased payment transactions for acquiring goods and services from nonemployees. The requirements of Topic 718 should be applied to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The adoption of this guidance is not expected to have a material impact on the Company’s results of operation, financial position or disclosures. In February 2016, the FASB issued guidance to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Previous lease accounting was criticized for failing to meet the needs of users of financial statements because it did not always provide a faithful representation of leasing transactions. In particular, it did not require lessees to recognize assets and liabilities arising from operating leases on the balance sheet. The guidance is effective for annual and interim periods beginning after December 15, 2018. The adoption of this guidance is not expected to have a material impact on the Company’s results of operation, financial position or disclosures. There are no additional accounting pronouncements issued or effective during the three or six months ended June 30, 2018 that have had, or are expected to have, an impact on our financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, and income tax valuation allowance. Inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts were the principal areas of estimation that had been reflected in the financial statements related to discontinued operations.
Stock-Based Payment Arrangements	Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, warrants, and restricted stock grants are measured at their fair value on the awards’ grant date typically using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees
Stock-Based Compensation	Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met.
Net Loss Per Share	Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.
Revenue Recognition	Revenue Recognition During the quarter ended June 30, 2016, the Company sold its consumer probiotic business, from which it had historically generated revenues. As a result of this sale, the Company is no longer generating revenues.
Concentrations	Concentrations In June of 2016, the Company sold its consumer probiotics business, as such the Company is no longer dependent on key suppliers to continue to operate the consumer probiotics business. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2018, the uninsured portion of this balance was $3,690,530. As of December 31, 2017, the uninsured portion of this balance was $5,916,143.
Warrant [Member]
Warrants	Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued.

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense Recognized	The Company recognized stock-based compensation on all employee and non-employee For the For the For the Six For the Six Research and development $ 9,192 $ 5,643 $ 18,048 $ 12,257 General and administrative 97,114 117,105 206,582 282,509 Total Stock based compensation $ 106,306 $ 122,748 $ 224,630 $ 294,766

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Text Block [Abstract]
Summary of Warrant Activity	A summary of warrant activity for the year ended December 31, 2017 and the six months ended June 30, 2018 is as follows: Warrants Weighted Average Price Balance - December 31, 2016 17,559 $ 1.50 Granted 2,177,425 3.10 Exercised — — Expired (17,559 ) 1.50 Balance - December 31, 2017 2,177,425 3.10 Granted 900,000 2.00 Exercised — — Expired — — Balance - June 30, 2018 3,077,425 $ 2.78
Summary of Warrants Outstanding	The warrants outstanding as of June 30, 2018 are as follows: Exercise Price Warrants Outstanding Expiration Date $ 3.10 48,387 9/19/2022 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 2.00 900,000 4/10/2023 3,077,425

Subsequent Event (Tables)

Subsequent Event (Tables)	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Pro Forma Shareholder's Equity Table	The following table sets forth the Company’s Total Shareholders’ Equity position as of June 30, 2018, as adjusted on a pro forma Oragenics, Inc. Pro Forma Shareholder’s Equity (U.S. dollars) Total Shareholders’ Equity as of June 30, 2018 $ 3,650,580 Net Proceeds from July 17, 2018 Public Offering 12,300,000 Pro forma Total Shareholders’ Equity, as of June 30, 2018, as adjusted $ 15,950,580

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues			$ 0
Net loss	$ 2,281,289	$ 1,220,866	4,400,686	$ 3,203,562
Cash used in operations			3,647,459	$ 3,665,508
Accumulated deficit	$ 105,860,153		$ 105,860,153		$ 101,400,797

Significant Accounting Polici21

Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Uninsured portion of cash balance	$ 3,690,530	$ 5,916,143

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense Recognized (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total Stock based compensation	$ 106,306	$ 122,748	$ 224,630	$ 294,766
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total Stock based compensation	9,192	5,643	18,048	12,257
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total Stock based compensation	$ 97,114	$ 117,105	$ 206,582	$ 282,509

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	Jun. 22, 2018	Jun. 22, 2017	Feb. 09, 2017	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock option awards				128,000			105,600		128,000	105,600
Weighted-average grant date fair value				$ 1.52			$ 3.60		$ 1.52	$ 3.60
Stock options vested									116,199
Stock options forfeited									0
Number of stock options, exercised									0
2012 Equity Incentive Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Number of additional shares authorized for issuance under an established share-based compensation plan	1,500,000
2012 Equity Incentive Plan [Member] | Non-employee Directors [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock option awards	14,000	14,000
Exercise price	$ 1.52	$ 3.70
Annual retainer amount for the threshold of stock precluded from selling									$ 270,000
2012 Equity Incentive Plan [Member] | Non-employee Directors [Member] | Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted shares awarded to each non-employee director	4,000		4,000
Restricted shares vest in each quarter end					1,000	1,000	1,000	1,000
Restricted shares vesting rights									Under the Company’s 2012 Equity Incentive Plan, of which, 1,000 restricted shares vested at the end of each calendar quarter in 2017.
2012 Equity Incentive Plan [Member] | Management [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock option awards	62,000	45,500
Exercise price	$ 1.52	$ 3.70
2012 Equity Incentive Plan [Member] | Staff [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock option awards	10,000	4,100
Exercise price	$ 1.52	$ 3.70

Warrants - Additional Informati

Warrants - Additional Information (Detail) - $ / shares	Apr. 06, 2018	Jun. 30, 2018	Dec. 31, 2017
Equity [Abstract]
Common stock issued during period	900,000
Warrant exercise price	$ 2
Warrant expiration period	5 years
Warrant exercisable period	6 months
Class of warrant issued	900,000	900,000	2,177,425

Warrants - Summary of Warrant A

Warrants - Summary of Warrant Activity (Detail) - $ / shares	Apr. 06, 2018	Jun. 30, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Warrants, Beginning balance		2,177,425	17,559
Warrants, Granted	900,000	900,000	2,177,425
Warrants, Exercised		0	0
Warrants, Expired			(17,559)
Warrants, Ending balance		3,077,425	2,177,425
Weighted Average Price, Granted	$ 2
Weighted Average Price, Ending balance	$ 2
Weighted Average [Member]
Class of Warrant or Right [Line Items]
Weighted Average Price, Beginning balance		$ 3.10	$ 1.50
Weighted Average Price, Granted		2	3.10
Weighted Average Price, Exercised		0	0
Weighted Average Price, Expired			1.50
Weighted Average Price, Ending balance		$ 2.78	$ 3.10

Warrants - Summary of Warrants

Warrants - Summary of Warrants Outstanding (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2018	Apr. 06, 2018	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Exercise Price		$ 2
Warrants Outstanding	3,077,425		2,177,425	17,559
Class One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.10
Warrants Outstanding	48,387
Expiration Date	Sep. 19, 2022
Class Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.10
Warrants Outstanding	462,106
Expiration Date	May 10, 2024
Class Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.10
Warrants Outstanding	602,414
Expiration Date	Jul. 25, 2024
Class Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.10
Warrants Outstanding	1,064,518
Expiration Date	Nov. 8, 2024
Class Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2
Warrants Outstanding	900,000
Expiration Date	Apr. 10, 2023

Short-Term Notes Payable - Addi

Short-Term Notes Payable - Additional Information (Detail) - USD ($)	Mar. 10, 2018	Jul. 24, 2017	Mar. 10, 2017	Jul. 24, 2016	Mar. 01, 2016	Jun. 30, 2018	Dec. 31, 2017
Short-term Debt [Line Items]
Short term notes payable for financing insurance policies						$ 20,912	$ 80,478
Product Liability Insurance Financing [Member] | Short Term Note Payable [Member]
Short-term Debt [Line Items]
Debt instrument face amount	$ 28,915		$ 31,985		$ 49,395
Interest rate on short-term note	5.09%		6.18%		5.93%
Principal and interest first required payment date	Apr. 10, 2018		Apr. 10, 2017		Apr. 10, 2016
Short-term notes payable amortization period	11 months		10 months		10 months
Final payment date of short-term note payable	Feb. 10, 2019		Jan. 2, 2018		Jan. 4, 2017
Directors' and Officers' Liability Insurance Financing [Member] | Short Term Note Payable [Member]
Short-term Debt [Line Items]
Debt instrument face amount		$ 140,062		$ 111,730
Interest rate on short-term note		5.09%		4.89%
Principal and interest first required payment date		Aug. 24, 2017		Aug. 24, 2016
Short-term notes payable amortization period		11 months		11 months
Final payment date of short-term note payable		Jun. 25, 2018		Jun. 21, 2017

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended			6 Months Ended
	Nov. 30, 2017USD ($)	Oct. 31, 2017	Oct. 31, 2016USD ($)	Jun. 30, 2018USD ($)Milestone
UFRF License Agreement [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				5.00%
Company's obligation to pay from all revenue received from sublicenses				22.00%
One-time commercialization fee monthly amount for calculation				$ 5,000
Post-commercialization minimum royalty payments				50,000
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount				$ 2,000,000
One-time additional payment to UFRF as a percentage of total royalties due to UFRF				10.00%
Minimum annual maintenance payment on license agreement				$ 10,000
Quarterly maintenance payment to UFRF under installment plan				$ 2,500
Termination notice period				90 days
Texas A and M University License [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				5.00%
Post-commercialization minimum royalty payments				$ 100,000
Initial payment to Texas A&M				5,000
Minimum consideration for the continuation of the license agreement				$ 15,000
Number of milestones achieved | Milestone				0
Texas A and M University License [Member] | Amendment [Member]
Commitment And Contingencies [Line Items]
Minimum consideration for the continuation of the license agreement			$ 25,000
Texas A and M University License [Member] | Phase 1 Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 1, 2019
Milestone payment under licensing agreement				$ 50,000
Texas A and M University License [Member] | Phase 2 Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 1, 2022
Milestone payment under licensing agreement				$ 100,000
Texas A and M University License [Member] | Phase 3 Clinical Trial [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 1, 2025
Milestone payment under licensing agreement				$ 150,000
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]
Commitment And Contingencies [Line Items]
Date of milestone achievement under licensing agreement with Texas A&M				Jun. 1, 2026
Milestone payment under licensing agreement				$ 400,000
Texas A and M University License [Member] | Minimum [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				2.00%
Lantibiotic ECC [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				10.00%
Company's obligation to pay from all revenue received from sublicenses	25.00%			25.00%
Number of milestones achieved | Milestone				0
Royalty rate based on percentage of net sales	10.00%
Lantibiotic ECC [Member] | Scenario, Previously Reported [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from all revenue received from sublicenses		50.00%
Royalty rate based on percentage of product profit		25.00%
Lantibiotic ECC [Member] | New Product Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Lantibiotic ECC [Member] | New Drug Application [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement	$ 25,000,000
Milestone measurement period	6 months
Lantibiotic ECC [Member] | Regulatory Approval Application Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 25,000,000
Milestone measurement period				6 months
Lantibiotic ECC [Member] | New Indication Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Lantibiotic ECC [Member] | Minimum [Member]
Commitment And Contingencies [Line Items]
Advancement expended amount for lantibiotic program	$ 1,200,000
Oral Mucositis ECC [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from percentage of selling price of product				12.00%
Company's obligation to pay from all revenue received from sublicenses	25.00%			25.00%
Number of milestones achieved | Milestone				0
Oral Mucositis ECC [Member] | Scenario, Previously Reported [Member]
Commitment And Contingencies [Line Items]
Company's obligation to pay from all revenue received from sublicenses		50.00%
Oral Mucositis ECC [Member] | New Product Application [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement	$ 27,500,000
Milestone measurement period	6 months
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Oral Mucositis ECC [Member] | Regulatory Approval Application Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 27,500,000
Milestone measurement period				6 months
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]
Commitment And Contingencies [Line Items]
Milestone payment under licensing agreement				$ 5,000,000
Milestone measurement period				6 months
Oral Mucositis ECC [Member] | Maximum [Member]
Commitment And Contingencies [Line Items]
Maturity of interest bearing promissory note				12 months

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jun. 27, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
ProBiora Health, LLC [Member] | Discontinued Operations Disposed of by Sale [Member]
Related Party Transaction [Line Items]
Sales price of business	$ 1,700,000
Cash received from sale of business	1,250,000
Receivable from sale of business	$ 450,000
Interest rate	1.00%
Contingent consideration payment period	10 years
Contingent consideration						$ 0	$ 0
ProBiora Health, LLC [Member] | Discontinued Operations Disposed of by Sale [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Contingent consideration	$ 2,000,000
Intrexon [Member] | Oral Mucositis and Lantibiotic Exclusive Channel Collaboration Agreements [Member]
Related Party Transaction [Line Items]
Cash paid to Intrexon Corporation		$ 89,216	$ 0	$ 159,233	$ 524,620
Accounts payable and accrued expenses		$ 142,333		$ 142,333		$ 39,457
Principal Owner [Member] | Intrexon [Member]
Related Party Transaction [Line Items]
Percentage of outstanding common stock		25.40%	31.40%	25.40%	31.40%

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail)

May 10, 2019

Jun. 22, 2018shares

Apr. 06, 2018$ / sharesshares

Mar. 09, 2018shares

Jan. 25, 2018shares

Jan. 08, 2018$ / sharesshares

Nov. 08, 2017USD ($)$ / sharesshares

Jul. 25, 2017USD ($)$ / sharesshares

May 10, 2017USD ($)Investor$ / sharesshares

Feb. 09, 2017shares

Dec. 31, 2017$ / sharesshares

Sep. 30, 2017shares

Jun. 30, 2017USD ($)shares

Mar. 31, 2017shares

Jun. 30, 2018$ / sharesshares

Dec. 31, 2017$ / sharesshares

Jan. 19, 2018shares

Jan. 18, 2018shares

Jan. 31, 2017shares

Class of Stock [Line Items]

Number of authorized shares of all classes of our capital stock

120,000,000

Common stock, shares authorized

45,000,000

200,000,000

200,000,000

200,000,000

45,000,000

100,000,000

Common stock par value | $ / shares

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Stock issued during period shares reverse stock splits ratio

0.10

Effective date of common stock split

Jan. 19, 2018

Common stock, shares outstanding

4,928,335

6,102,635

4,928,335

4,900,000

Preferred stock, shares authorized

50,000,000

50,000,000

50,000,000

Fractional share from reverse stock split

0

Warrants granted

900,000

900,000

2,177,425

Sale of stock, price per share | $ / shares

$ 0.001

Warrant exercise price | $ / shares

$ 2

Common stock issued during period

900,000

Common stock issued, offering price per share | $ / shares

$ 2

Term of warrants

5 years

Non-exercisable term of warrants

6 months

Number of accredited investors | Investor

3

Warrants exercise price per share | $ / shares

$ 2

Intrexon [Member] | Unsecured Non-convertible Promissory Note [Member]

Class of Stock [Line Items]

Debt instrument, face amount | $

$ 2,400,000

Debt instrument, accrued interest | $

$ 3,400,000

2012 Equity Incentive Plan [Member] | Restricted Stock [Member]

Class of Stock [Line Items]

Unrecognized compensation expense | $

$ 29,372

Scenario, Previously Reported [Member]

Class of Stock [Line Items]

Common stock, shares authorized

450,000,000

Common stock, shares outstanding

49,000,000

Series B Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

6,600,000

Convertible into shares of common stock

1,320,002

Fixed conversion price | $ / shares

$ 2.50

Preferred stock, par value | $ / shares

$ 0.001

Voting rights

No voting rights

Convertible preferred stock, terms of conversion

Conversion of one share of Series B Preferred Stock into two shares of Common Stock.

Series B Preferred Stock [Member] | Private Placement [Member]

Class of Stock [Line Items]

Gross proceed of preferred stock | $

$ 3,300,000

Series B Preferred Stock [Member] | Private Placement [Member] | Fall 17 Warrant [Member]

Class of Stock [Line Items]

Term of warrants

7 years

Non-exercisable term of warrants

6 months

Warrants to purchase common stock, issued

1,064,518

Warrants exercise price per share | $ / shares

$ 3.10

Series C Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

1,000

Preferred stock, par value | $ / shares

$ 0.001

Preferred stock dividend rate

12.00%

Preferred stock issued as dividend

1.733

Series C Preferred Stock [Member] | Intrexon [Member]

Class of Stock [Line Items]

Number of shares of common stock issued in connection with conversion of preferred stock

100

Series C Preferred Stock [Member] | Scenario, Forecast [Member]

Class of Stock [Line Items]

Preferred stock dividend rate

20.00%

Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Number of shares of preferred stock converted

2,583,000

Common Stock [Member]

Class of Stock [Line Items]

Number of shares of common stock issued in connection with conversion of preferred stock

258,300

Series A Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, shares authorized

12,000,000

Convertible into shares of common stock

1,200,001

Fixed conversion price | $ / shares

$ 2.50

Preferred stock, par value | $ / shares

$ 0.001

Voting rights

No voting rights

Series A Preferred Stock [Member] | Maximum [Member]

Class of Stock [Line Items]

Gross proceed of preferred stock | $

$ 3,000,000

Series A Preferred Stock [Member] | Preferred Stock Issued Upon Initial Closing [Member]

Class of Stock [Line Items]

Term of warrants

7 years

Non-exercisable term of warrants

6 months

Gross proceed of preferred stock | $

$ 1,302,000

Warrants to purchase common stock, issued

462,106

Warrants exercise price per share | $ / shares

$ 3.10

Series A Preferred Stock [Member] | Preferred Stock Issued Upon Second Closing [Member]

Class of Stock [Line Items]

Term of warrants

7 years

Non-exercisable term of warrants

6 months

Gross proceed of preferred stock | $

$ 1,698,000

Warrants to purchase common stock, issued

602,414

Warrants exercise price per share | $ / shares

$ 3.10

Non-employee Directors [Member] | 2012 Equity Incentive Plan [Member] | Restricted Stock [Member]

Class of Stock [Line Items]

Restricted shares awarded to each non-employee director

4,000

4,000

Restricted shares vest in each quarter end

1,000

1,000

1,000

1,000

Amendment [Member]

Class of Stock [Line Items]

Number of authorized shares of all classes of our capital stock

270,000,000

Common stock, shares authorized

200,000,000

250,000,000

Amendment Two [Member]

Class of Stock [Line Items]

Common stock, shares authorized

450,000,000

450,000,000

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($)	Jul. 17, 2018	Apr. 06, 2018	Jun. 30, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Exercise price of each warrant		$ 2
Common shares issued during public offering		900,000
Allotment upon exercise of underwriters option ,shares			0	0
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from public offering	$ 13,800,000
Allotment upon exercise of underwriters option ,shares	13,800,000
Increase decrease in common stock	4.99%
Notice Period	61 days
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Share price per unit	$ 3
Common shares issued during public offering	4,436,000
Conversion price	$ 1
Trading period	30 days
Average trading volume for measurement	$ 175,000
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Proceeds from public offering	$ 12,300,000
Subsequent Event [Member] | Capital Unit, Class A [Member]
Subsequent Event [Line Items]
Share price per unit	$ 1
Number of common stock consist in each unit	1
Number of warrant consist in each unit	1
Common stock warrants term	7 years
Exercise price of each warrant	$ 1
Subsequent Event [Member] | Capital Unit, Class B [Member]
Subsequent Event [Line Items]
Share price per unit	$ 1
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Increase decrease in common stock	9.99%
Subsequent Event [Member] | Underwriter [Member]
Subsequent Event [Line Items]
Allotment upon exercise of underwriters option ,shares	1,800,000
Subsequent Event [Member] | Series D Preferred Stock [Member]
Subsequent Event [Line Items]
Total preferred stock issued	9,364,000
Preferred stock, shares outstanding	8,760,000
Subsequent Event [Member] | Series D Preferred Stock [Member] | Capital Unit, Class B [Member]
Subsequent Event [Line Items]
Number of preferred stock consist in each unit	1
Preferred stock convertible into common stock,warrants	1

Subsequent Events - Pro Forma S

Subsequent Events - Pro Forma Shareholder's Equity Table (Detail) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Total Shareholders' Equity as of June 30, 2018	$ 3,650,580	$ 6,316,309
Pro forma Total Shareholders' Equity, as of June 30, 2018, as adjusted	15,950,580
July 17, 2018 [Member]
Subsequent Event [Line Items]
Net Proceeds from July 17, 2018 Public Offering	$ 12,300,000